Combination therapy using molecules that bind to the TCR
By targeting distinct TCRαV and TCRβV regions with sequential administration, the method addresses the limitations of anti-CD3e monoclonal antibodies, enhancing T cell activation for cancer therapy while reducing cytokine storm and neurotoxicity.
JP2026517755APending Publication Date: 2026-06-02MARENGO THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- MARENGO THERAPEUTICS INC
- Filing Date
- 2024-04-26
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517755000001_ABST
Abstract
This specification provides methods for treating a disease or condition in a subject, or for using combination therapy with agents that bind to the alpha variable region of the T cell receptor (TCRαV) and / or the beta variable region of the T cell receptor (TCRβV).
Need to check novelty before this filing date? Find Prior Art